Patients
We studied the medical records of all locally advanced and advanced NSCLC patients treated at the Jiangsu Cancer Hospital between May 2018 and March 2021 and identified patients who received the PD-1 inhibitor alone or in combination with the chemotherapy and/or the bevacizumab therapy and screened patients who met one or more of the following criteria: positive for hepatitis B surface antigen; HCV - RNA positive; Syphilis antibody positive. All patients included in this study had at least one measurable disease. This study was approved by the Academic Ethics Committee of Jiangsu Cancer Hospital.